After Tender Comes Hospitals: China Mulls Restoring Second-Round Drug Price Negotiations
This article was originally published in PharmAsia News
Executive Summary
Banned two years ago, second-round drug price negotiations may be making a comeback in China, and the impact could be far-reaching for pharma companies.